Purging of Autologous Bone Marrow for Transplantation: The Protection and Selection of the Hematopoietic Progenitor Cell

Elizabeth J. Shpall*, Salomon M. Stemmer, Charles F. Johnston, Lisa Hami, Scott I. Bearman, Ronald Berenson, Roy B. Jones

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Autologous bone marrow transplantation (ABMT) is the treatment of choice for selected patients with acute myelogenous leukemia, non-Hodgkin's lymphoma, and poor prognosis breast cancer. A possible limitation of this approach is that clonogenic tumor cells could be collected and infused back into the patient along with the normal bone marrow. The major emphasis in our laboratory has been the development of marrow purging regimens for breast cancer patients. This paper describes two investigative approaches hematopoietic progenitor cell protection and selection. We describe how the use of G-CSF in the patients who receive positively selected marrow shortens the rate of engraftment.

Original languageEnglish
Pages (from-to)45-54
Number of pages10
JournalJournal of Hematotherapy and Stem Cell Research
Volume1
Issue number1
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Dive into the research topics of 'Purging of Autologous Bone Marrow for Transplantation: The Protection and Selection of the Hematopoietic Progenitor Cell'. Together they form a unique fingerprint.

Cite this